The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
Open accessAbstract
We have previously defined a panel of fully human CD20 mAb. Most of these were unexpectedly efficient in their ability to recruit C1q to the surface of CD20-positive cells and mediate tumor lysis via activation of the classical pathway of complement. This complement-dependent cytotoxicity (CDC) potency appeared to relate to the unusually slow off-rate of these human Abs. However, we now present epitope-mapping data, which indicates that all human mAb bind a novel region of CD20 that may influence CDC potency. Epitope mapping, using both mutagenesis studies and overlapping 15-mer peptides of the extracellular loops of CD20, defined the amino acids required for binding by an extensive panel of mouse and human mAb. Binding by rituximab and mouse CD20 mAb, had an absolute requirement for alanine and proline at positions 170 and 172, respectively, within the large extracellular loop of CD20. Surprisingly, however, all of the human CD20 mAb recognize a completely novel epitope located N-terminally of this motif, also including the small extracellular loop of CD20. Thus, although off-rate may influence biological activity of mAb, another critical factor for determining CDC potency by CD20 mAb appears to be the region of the target molecule they recognize. We conclude that recognition of the novel epitope cooperates with slow off-rate in determining the activity of CD20 Ab in activation of complement and induction of tumor cell lysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Teeling, J. L. (2004) · Blood · doi:10.1182/blood-2004-01-0039 · Cited by 630
Self-citationCD20: a regulator of cell-cycle progression of B lymphocytes
Tedder, T. F., & Engel, P. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90276-3 · Cited by 590
Golay, J., Lazzari, M., Facchinetti, V., Bernasconi, S., Borleri, G., Barbui, T., Rambaldi, A., & Introna, M. (2001) · Blood · doi:10.1182/blood.v98.12.3383 · Cited by 428
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
Cragg, M. S., Morgan, S. M., Chan, H. T. C., Morgan, B. P., Filatov, A. V., Johnson, P. W. M., French, R. R., & Glennie, M. J. (2003) · Blood · doi:10.1182/blood-2002-06-1761 · Cited by 390
Self-citationSignaling events involved in anti-CD20-induced apoptosis of malignant human B cells
Shan, D., Ledbetter, J. A., & Press, O. W. (2000) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620050016 · Cited by 385
Byrd, J. C., Kitada, S., Flinn, I. W., Aron, J. L., Pearson, M., Lucas, D., & Reed, J. C. (2002) · Blood · doi:10.1182/blood.v99.3.1038 · Cited by 367
The Biology of CD20 and Its Potential as a Target for mAb Therapy
Cragg, M. S., Walshe, C. A., Ivanov, A. O., & Glennie, M. J. (2004) · Current Directions in Autoimmunity · doi:10.1159/000082102 · Cited by 364
Self-citationMonoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
Press, O., Appelbaum, F., Ledbetter, J., Martin, P., Zarling, J., Kidd, P., & Thomas, E. (1987) · Blood · doi:10.1182/blood.v69.2.584.584 · Cited by 361
Laskey, R. A., Fairman, M. P., & Blow, J. J. (1989) · Science · doi:10.1126/science.2683076 · Cited by 361
Kennedy, A. D., Beum, P. V., Solga, M. D., DiLillo, D. J., Lindorfer, M. A., Hess, C. E., Densmore, J. J., Williams, M. E., & Taylor, R. P. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.3280 · Cited by 359
Bubien, J. K., Zhou, L. J., Bell, P. D., Frizzell, R. A., & Tedder, T. F. (1993) · The Journal of cell biology · doi:10.1083/jcb.121.5.1121 · Cited by 355
Timmerman, P., Beld, J., Puijk, W. C., & Meloen, R. H. (2005) · ChemBioChem · doi:10.1002/cbic.200400374 · Cited by 295
High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice
Fishwild, D. M., O'Donnell, S. L., Bengoechea, T., Hudson, D. V., Harding, F., Bernhard, S. L., Jones, D., Kay, R. M., Higgins, K. M., Schramm, S. R., et al. (1996) · Nature Biotechnology · doi:10.1038/nbt0796-845 · Cited by 266
Szöllósi, J., Horejsí, V, Bene, L., Angelisová, P., & Damjanovich, S. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.7.2939 · Cited by 264
Glennie, M. J., McBride, H. M., Worth, A. T., & Stevenson, G. T. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.7.2367 · Cited by 263
Self-citationThe mechanisms of action of rituximab in the elimination of tumor cells
Johnson, P., & Glennie, M. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50025 · Cited by 247
Self-citationContrasting IgG Structures Reveal Extreme Asymmetry and Flexibility
Saphire, E. O., Stanfield, R. L., Max Crispin, M. D., Parren, P. W. H. I., Rudd, P. M., Dwek, R. A., Burton, D. R., & Wilson, I. A. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00244-9 · Cited by 243
Self-citationBeum, P. V., Kennedy, A. D., Williams, M. E., Lindorfer, M. A., & Taylor, R. P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.4.2600 · Cited by 239
Chan, H. T. C., Hughes, D., French, R. R., Tutt, A. L., Walshe, C. A., Teeling, J. L., Glennie, M. J., & Cragg, M. S. (2003) · PubMed · Cited by 211
Self-citationManshouri, T., Do, K.-A., Wang, X., Giles, F. J., O'Brien, S. M., Saffer, H., Thomas, D., Jilani, I., Kantarjian, H. M., Keating, M. J., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1639 · Cited by 204
Ghetie, M.-A., Bright, H., & Vitetta, E. S. (2001) · Blood · doi:10.1182/blood.v97.5.1392 · Cited by 191
Golay, J. T., Clark, E. A., & Beverley, P. C. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.6.3795 · Cited by 175
Store-operated Cation Entry Mediated by CD20 in Membrane Rafts
Li, H., Ayer, L. M., Lytton, J., & Deans, J. P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308802200 · Cited by 172
Polyak, M. J., & Deans, J. P. (2002) · Blood · doi:10.1182/blood.v99.9.3256 · Cited by 159
Renaissance of cancer therapeutic antibodies
Glennie, M. J., & van de Winkel, J. G. J. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02714-4 · Cited by 155
Self-citationRapid Redistribution of CD20 to a Low Density Detergent-insoluble Membrane Compartment
Deans, J. P., Robbins, S. M., Polyak, M. J., & Savage, J. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.1.344 · Cited by 151
Tedder, T. F., Forsgren, A., Boyd, A., Nadler, L. M., & Schlossman, S. F. (1986) · European Journal of Immunology · doi:10.1002/eji.1830160802 · Cited by 146
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia
Jilani, I. B., O'Brien, S. M., Manshuri, T., Thomas, D. A., Thomázy, V. A., Imam, M., Naeem, S., Verstovšek, S., Kantarjian, H. M., Giles, F. J., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0055 · Cited by 136
Mice carrying a CD20 gene disruption
O’Keefe, T. L., Williams, G. T., Davies, S. L., & Neuberger, M. S. (1998) · Immunogenetics · doi:10.1007/s002510050412 · Cited by 129
Signaling antibodies in cancer therapy
Cragg, M. S., French, R. R., & Glennie, M. J. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)00010-2 · Cited by 119
Self-citationPolyak, M. J., Tailor, S. H., & Deans, J. P. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.7.3242 · Cited by 112
Perosa, F., Favoino, E., Caragnano, M. A., & Dammacco, F. (2005) · Blood · doi:10.1182/blood-2005-04-1769 · Cited by 110
Structural organization of the human MS4A gene cluster on Chromosome 11q12
Liang, Y., Buckley, T. R., Tu, L., Langdon, S. D., & Tedder, T. F. (2001) · Immunogenetics · doi:10.1007/s002510100339 · Cited by 106
Tutt, A. L., French, R. R., Illidge, T., Honeychurch, J., McBride, H. M., Penfold, C. A., Fearon, D. T., Parkhouse, R. M. E., Klaus, G. G. B., & Glennie, M. J. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.3176 · Cited by 95
Self-citationStructural aspects of antibody-antigen interaction revealed through small random peptide libraries
Slootstra, J. W., Puijk, W. C., Ligtvoet, G. J., Langeveld, J., & Meloen, R. H. (1996) · Molecular Diversity · doi:10.1007/bf01721323 · Cited by 85
Self-citationCD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines
Leveillé, C., Al‐Daccak, R., & Mourad, W. M. (1999) · European Journal of Immunology · Cited by 81
Beum, P. V., Kennedy, A. D., & Taylor, R. P. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.03.012 · Cited by 54
Monoclonal antibody therapy of chronic lymphocytic leukemia
Cheson, B. D. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0010-0 · Cited by 50
Pagel, J. M., Laugen, C., Bonham, L., Hackman, R. C., Hockenbery, D. M., Bhatt, R., Hollenback, D., Carew, H., Singer, J. W., & Press, O. W. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2352 · Cited by 43
Shan, D., Gopal, A. K., & Press, O. W. (2001) · PubMed · Cited by 26
Monoclonal antibodies in the management of newly diagnosed, aggressive B-cell lymphoma.
Coiffier, B. (2003) · PubMed · Cited by 16
Cited by
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
de Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Self-citationDevelopment trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,026
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
Diebolder, C. A., Beurskens, F. J., de Jong, R. N., Koning, R. I., Strumane, K., Lindorfer, M. A., Voorhorst, M., Ugurlar, D., Rosati, S., Heck, A. J. R., et al. (2014) · Science · doi:10.1126/science.1248943 · Cited by 796
Self-citation
Metadata
- Authors
- Teeling, J. L., Mackus, W. J. M., Wiegman, L. J. J. M., van den Brakel, J. H. N., Beers, S. A., French, R. R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J. W., Parren, P. W. H. I., Glennie, M. J., & van de Winkel, J. G. J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-07-01
- Volume
- 177
- Issue
- 1
- Pages
- 362-371
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2122725450
- Cited by
- 609
- References
- 41
- FWCI
- 22.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.